FDA inspection
Glenmark Pharmaceuticals Inc., USA: FDA inspection ending Nov 15, 2012
FDA inspection 807127 · Mahwah, NJ
Key facts
| Inspection ID | 807127 |
|---|---|
| Firm | Glenmark Pharmaceuticals Inc., USA |
| FEI number | 3005658103 |
| Address | 750 Corporate Dr |
| City | Mahwah |
| State | NJ |
| ZIP | 07430-2009 |
| Fiscal year | 2013 |
| Inspection end date | Nov 15, 2012 |
| Project area | Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data